Cargando…
Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study
BACKGROUND: Pirfenidone is an anti-fibrotic agent shown to slow the progression of idiopathic pulmonary fibrosis (IPF). However, its effectiveness in association with serological autoimmune features in IPF remains unclear. METHODS: We retrospectively reviewed the medical records of patients with IPF...
Autores principales: | Song, Myung Jin, Lee, Sang Hoon, Jung, Ji Ye, Kang, Young Ae, Park, Moo Suk, Kim, Young Sam, Chang, Joon, Kim, Song Yee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091553/ https://www.ncbi.nlm.nih.gov/pubmed/33941141 http://dx.doi.org/10.1186/s12890-021-01516-4 |
Ejemplares similares
-
Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital
por: Song, Myung Jin, et al.
Publicado: (2020) -
Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis: Assessment according to GAP Stage
por: Song, Myung Jin, et al.
Publicado: (2019) -
Pirfenidone-Induced Photosensitivity in a Patient with Idiopathic Pulmonary Fibrosis
por: Kim, Ho-Jin, et al.
Publicado: (2018) -
Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study
por: Lee, Ho Young, et al.
Publicado: (2023) -
Prognostic impact of the ratio of the main pulmonary artery to that of the aorta on chest computed tomography in patients with idiopathic pulmonary fibrosis
por: Choi, Ji Soo, et al.
Publicado: (2019)